PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual DisorderBy 23Scadoo, January 9, 2017
Long $PTN
http://finance.yahoo.com/news/amag-pharmaceuticals-palatin-technologies-enter-130000071.html
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Why is AMAG down $12.60 on minor news? Any insight on this issue. I have been watching this stock and considering buying, is there more to the issue. Could it be manipulation by larger players. Down 35% it a bit extreme. Any ideas.